Workflow guide · Competitive research
How Analysts Monitor Biotech Competitors by Target and Indication
Create a peer-monitoring system that captures indirect evidence across a therapeutic landscape.
The situation
When this workflow becomes useful
Coverage companies compete in drug classes where new data from a private company or a differently positioned program can change expectations.
Best fit
Sell-side, buy-side, independent, and corporate analysts responsible for ongoing biotech company or therapeutic-area coverage.
The challenge
Why the obvious approach breaks down
Traditional ticker lists are too narrow. Company names, program codes, target spellings, modalities, and indications change, creating blind spots.
How to think about the task
The reasoning behind the workflow
Ticker watchlists are poorly suited to target-level research. Relevant evidence may come from a private company, a renamed program, a different modality, or a trial in an adjacent indication. Analysts need an entity map that survives those changes.
The objective is not to collect every program mentioning the target. It is to define which programs can inform efficacy, safety, development strategy, regulatory precedent, or commercial differentiation.
Define several kinds of peers
Target peers answer biology questions, modality peers answer delivery or safety questions, and indication peers answer clinical and commercial questions. Labeling the relationship prevents inappropriate comparisons.
Monitor names and scientific language
Rules should include company names, program codes, target synonyms, modality terms, and disease terminology. The landscape table then normalizes incoming variants back to the same program and owner.
Record implication, not just activity
Every material competitor event should state what it teaches about a covered company. That implication may be strong, weak, conditional, or absent. Making the judgment explicit reduces vague competitive commentary.
Illustrative example
Illustrative private-company read-through
A private competitor presents early data using the same target but a different modality. The efficacy signal may support the target, while the safety and dosing profile may not transfer directly. The landscape records both relationships instead of calling the event uniformly positive.
The analyst can then update target confidence while preserving the covered company’s modality-specific questions.
Questions to answer before making a decision
- What kind of peer relationship exists?
- Which evidence is portable across the programs?
- Are names, codes, and ownership normalized?
- What does the event change for covered companies?
The workflow
A repeatable way to do the work
- 01
Create a landscape table with company, program, target, modality, indication, stage, and next event.
- 02
Add keyword variants for program codes, target names, and disease terminology.
- 03
Classify incoming events by scientific, regulatory, commercial, or transaction relevance.
- 04
Compare each event with the differentiation claims of covered companies.
- 05
Refresh the landscape after conferences, partnerships, discontinuations, and major readouts.
Monitoring checklist
Signals to keep visible
Common mistakes
- Tracking only public-company tickers
- Using a single target keyword
- Updating the landscape only before major reports
Output and outcome
What good looks like
Deliverable
A living target landscape linked to event alerts, upcoming catalysts, and explicit implications for covered companies.
Practical outcome
The analyst detects competitive evidence earlier and can explain why an event outside the formal coverage list matters.
Where BioPharmSignal fits
Reduce the collection work around the decision.
Use LiveFeed and company pages for source-linked monitoring, the PDUFA Calendar for upcoming FDA milestones, and watchlists or alerts to keep the relevant tickers and keywords visible. The workflow still requires independent research and judgment.
Frequently asked questions
Who is this workflow for?
It is designed for biotech research analysts and adjacent biotech research users who need a repeatable, source-linked way to complete this task.
What should this workflow produce?
A living target landscape linked to event alerts, upcoming catalysts, and explicit implications for covered companies.
What is the practical benefit?
The analyst detects competitive evidence earlier and can explain why an event outside the formal coverage list matters.
Related workflows